{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T18:04:51Z","timestamp":1791569091976,"version":"4.3.4"},"reference-count":52,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,3]],"date-time":"2025-12-03T00:00:00Z","timestamp":1764720000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100007950","name":"Tanta University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007950","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Anais Brasileiros de Dermatologia"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.abd.2025.501255","type":"journal-article","created":{"date-parts":[[2025,12,24]],"date-time":"2025-12-24T19:51:16Z","timestamp":1766605876000},"page":"501255","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Tirzepatide in dermatology: cutaneous adverse events, emerging therapeutic roles, and cosmetic implications \u2013 A comprehensive review"],"prefix":"10.1016","volume":"101","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9990-6862","authenticated-orcid":false,"given":"Heba Saed","family":"El-Amawy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.abd.2025.501255_bib0005","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1056\/NEJMoa2410819","article-title":"SURMOUNT-1 Investigators. Tirzepatide for obesity treatment and diabetes prevention","volume":"392","author":"Jastreboff","year":"2025","journal-title":"N Engl J Med."},{"key":"10.1016\/j.abd.2025.501255_bib0010","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/molecules27134315","article-title":"Tirzepatide, a new era of dual-targeted treatment for diabetes and obesity: a mini-review","volume":"27","author":"Chavda","year":"2022","journal-title":"Molecules."},{"key":"10.1016\/j.abd.2025.501255_bib0015","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1007\/s13300-020-00981-0","article-title":"The role of tirzepatide, dual GIP and GLP-1 receptor agonist, in the management of type 2 diabetes: the SURPASS clinical trials","volume":"12","author":"Min","year":"2021","journal-title":"Diabetes Ther."},{"key":"10.1016\/j.abd.2025.501255_bib0020","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/S0140-6736(21)01324-6","article-title":"Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial","volume":"398","author":"Rosenstock","year":"2021","journal-title":"Lancet."},{"key":"10.1016\/j.abd.2025.501255_bib0025","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1172\/jci.insight.140532","article-title":"Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist","volume":"5","author":"Willard","year":"2020","journal-title":"JCI insight"},{"key":"10.1016\/j.abd.2025.501255_bib0030","doi-asserted-by":"crossref","first-page":"2909","DOI":"10.1038\/s41591-023-02597-w","article-title":"Tirzepatide after intensive lifestyle intervention in adults with overweight or obesity: the SURMOUNT-3 phase 3 trial","volume":"29","author":"Wadden","year":"2023","journal-title":"Nat Med."},{"key":"10.1016\/j.abd.2025.501255_bib0035","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1056\/NEJMoa2206038","article-title":"Tirzepatide once weekly for the treatment of obesity","volume":"387","author":"Jastreboff","year":"2022","journal-title":"N Engl J Med."},{"key":"10.1016\/j.abd.2025.501255_bib0040","doi-asserted-by":"crossref","first-page":"998","DOI":"10.2337\/dc22-1710","article-title":"Tirzepatide reduces appetite, energy intake, and fat mass in people with type 2 diabetes","volume":"46","author":"Heise","year":"2023","journal-title":"Diabetes Care ."},{"key":"10.1016\/j.abd.2025.501255_bib0045","doi-asserted-by":"crossref","first-page":"3509","DOI":"10.2147\/DDDT.S506957","article-title":"A Comprehensive Review on the Pharmacokinetics and Drug\u2212 Drug Interactions of Approved GLP-1 Receptor Agonists and a Dual GLP-1\/GIP Receptor Agonist","author":"Min","year":"2025","journal-title":"Drug Des Devel Ther."},{"key":"10.1016\/j.abd.2025.501255_bib0050","doi-asserted-by":"crossref","first-page":"1","DOI":"10.12775\/JEHS.2024.71.49544","article-title":"Will Tirzepatide become a game-changer in the pharmacological treatment of obesity?-literature review","volume":"71","author":"Dory\u0144","year":"2024","journal-title":"J Educ Health Sport."},{"key":"10.1016\/j.abd.2025.501255_bib0055","doi-asserted-by":"crossref","first-page":"388","DOI":"10.36557\/2674-8169.2025v7n2p388-415","article-title":"Tirzepatide vs. semaglutide in type 2 diabetes and obesity: a systematic review and meta-analysis of metabolic efficacy, weight loss, and cardiovascular safety","volume":"7","author":"de Mendon\u00e7a","year":"2025","journal-title":"Braz J Implantol Health Sci."},{"key":"10.1016\/j.abd.2025.501255_bib0060","doi-asserted-by":"crossref","first-page":"158","DOI":"10.2337\/dc24-S009","article-title":"Erratum. 9. pharmacologic approaches to glycemic treatment: Standards of care in diabetes\u20142024","volume":"47","author":"Elsayed","year":"2024","journal-title":"Diabetes Care"},{"key":"10.1016\/j.abd.2025.501255_bib0065","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1056\/NEJMoa2107519","article-title":"Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes","volume":"385","author":"Fr\u00edas","year":"2021","journal-title":"N Engl J Med."},{"key":"10.1016\/j.abd.2025.501255_bib0070","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1001\/jama.2022.0078","article-title":"Effect of subcutaneous tirzepatide vs placebo added to titrated insulin glargine on glycemic control in patients with type 2 diabetes: the SURPASS-5 randomized clinical trial","volume":"327","author":"Dahl","year":"2022","journal-title":"JAMA."},{"key":"10.1016\/j.abd.2025.501255_bib0075","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.metabol.2022.155248","article-title":"Recent guidelines for non-alcoholic fatty liver disease (NAFLD)\/fatty liver disease (FLD): are they already outdated and in need of supplementation?","volume":"136","author":"Valenzuela-Vallejo","year":"2022","journal-title":"Metabolism."},{"key":"10.1016\/j.abd.2025.501255_bib0080","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/ijms232314631","article-title":"Tirzepatide: a systematic update","volume":"23","author":"Forzano","year":"2022","journal-title":"Int J Mol Sci."},{"key":"10.1016\/j.abd.2025.501255_bib0085","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fendo.2023.1121387","article-title":"A systematic review of the safety of tirzepatide-a new dual GLP1 and GIP agonist-is its safety profile acceptable?","volume":"14","author":"Meng","year":"2023","journal-title":"Front Endocrinol."},{"key":"10.1016\/j.abd.2025.501255_bib0090","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fendo.2022.1004044","article-title":"Clinical perspectives on the use of the GIP\/GLP-1 receptor agonist tirzepatide for the treatment of type-2 diabetes and obesity","volume":"13","author":"Gallwitz","year":"2022","journal-title":"Front Endocrinol."},{"key":"10.1016\/j.abd.2025.501255_bib0095","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1210\/clinem\/dgad532","article-title":"Tirzepatide immunogenicity on pharmacokinetics, efficacy, and safety: analysis of data from phase 3 studies","volume":"109","author":"Mullins","year":"2024","journal-title":"J Clin Endocrinol Metab."},{"key":"10.1016\/j.abd.2025.501255_bib0100","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/S0140-6736(21)01443-4","article-title":"Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial","volume":"398","author":"Ludvik","year":"2021","journal-title":"Lancet."},{"key":"10.1016\/j.abd.2025.501255_bib0105","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1016\/S0140-6736(21)02188-7","article-title":"Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial","volume":"398","author":"Del Prato","year":"2021","journal-title":"Lancet."},{"key":"10.1016\/j.abd.2025.501255_bib0110","series-title":"Mounjaro (tirzepatide) prescribing information [Internet]","year":"2022"},{"key":"10.1016\/j.abd.2025.501255_bib0115","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/S0140-6736(23)01200-X","article-title":"Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial","volume":"402","author":"Garvey","year":"2023","journal-title":"Lancet."},{"key":"10.1016\/j.abd.2025.501255_bib0120","first-page":"1","article-title":"Tirzepatide-induced injection site reaction","volume":"15","author":"Mizumoto","year":"2023","journal-title":"Cureus."},{"key":"10.1016\/j.abd.2025.501255_bib0125","first-page":"181","article-title":"Cross-sectional analysis of adverse dermatologic events reported to the FDA after use of GLP-1 agonists","volume":"23","author":"Ituarte","year":"2024","journal-title":"J Drugs Dermatol."},{"key":"10.1016\/j.abd.2025.501255_bib0130","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1177\/00185787221125724","article-title":"Tirzepatide","volume":"58","author":"Baker","year":"2023","journal-title":"Hosp Pharm."},{"key":"10.1016\/j.abd.2025.501255_bib0135","first-page":"1","article-title":"Tirzepatide-induced biphasic anaphylactic reaction: a case report","volume":"15","author":"He","year":"2023","journal-title":"Cureus."},{"key":"10.1016\/j.abd.2025.501255_bib0140","first-page":"393","article-title":"Mounjaro (tirzepatide): prescribing information","volume":"10","author":"Lilly","year":"2022","journal-title":"Indianapolis ."},{"key":"10.1016\/j.abd.2025.501255_bib0145","first-page":"1","article-title":"A case report of systemic allergic reaction to the dual glucose-dependent insulinotropic polypeptide\/glucagon-like peptide-1 receptor agonist tirzepatide","volume":"16","author":"Le","year":"2024","journal-title":"Cureus."},{"key":"10.1016\/j.abd.2025.501255_bib0150","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1210\/jendso\/bvad016","article-title":"Adverse events related to tirzepatide","volume":"7","author":"Mishra","year":"2023","journal-title":"J Endocr Soc."},{"key":"10.1016\/j.abd.2025.501255_bib0155","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.jaad.2024.03.021","article-title":"Dermatologic findings associated with semaglutide use: a scoping review","volume":"91","author":"Tran","year":"2024","journal-title":"J Am Acad Dermatol."},{"key":"10.1016\/j.abd.2025.501255_bib0160","doi-asserted-by":"crossref","first-page":"413","DOI":"10.36849\/JDD.8605","article-title":"A retrospective comparative analysis of cutaneous adverse reactions in GLP-1 agonist therapies","volume":"24","author":"Daniel","year":"2025","journal-title":"J Drugs Dermatol."},{"key":"10.1016\/j.abd.2025.501255_bib0165","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1007\/s11695-020-05100-3","article-title":"Skin changes due to massive weight loss: histological changes and the causes of the limited results of contouring surgeries","volume":"31","author":"Rocha","year":"2021","journal-title":"Obes Surg."},{"key":"10.1016\/j.abd.2025.501255_bib0170","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1210\/jc.2015-3348","article-title":"Accumulation and changes in composition of collagens in subcutaneous adipose tissue after bariatric surgery","volume":"101","author":"Liu","year":"2016","journal-title":"J Clin Endocrinol Metab."},{"key":"10.1016\/j.abd.2025.501255_bib0175","first-page":"1","article-title":"Skin protein profile after major weight loss and its role in body contouring surgery","volume":"7","author":"Gallo","year":"2019","journal-title":"Plast Reconstr Surg Glob Open."},{"key":"10.1016\/j.abd.2025.501255_bib0180","doi-asserted-by":"crossref","first-page":"1907","DOI":"10.1016\/j.clnu.2024.06.034","article-title":"Metabolic effects of very-low calorie diet, semaglutide, or combination of the two, in individuals with type 2 diabetes mellitus","volume":"43","author":"Anyiam","year":"2024","journal-title":"Clin Nutr."},{"key":"10.1016\/j.abd.2025.501255_bib0185","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1001\/jamanetworkopen.2022.31982","article-title":"Weight loss outcomes associated with semaglutide treatment for patients with overweight or obesity","volume":"5","author":"Ghusn","year":"2022","journal-title":"JAMA Netw Open."},{"key":"10.1016\/j.abd.2025.501255_bib0190","doi-asserted-by":"crossref","DOI":"10.1111\/jocd.16716","article-title":"The role of GLP\u20101 agonists in esthetic medicine: exploring the impact of semaglutide on body contouring and skin health","volume":"24","author":"Haykal","year":"2025","journal-title":"J Cosmet Dermatol."},{"key":"10.1016\/j.abd.2025.501255_bib0195","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/asjof\/ojae069","article-title":"Soft tissue facial changes following massive weight loss secondary to medical and surgical bariatric interventions: a systematic review","volume":"6","author":"Jafar","year":"2024","journal-title":"Aesthet Surg J Open Forum."},{"key":"10.1016\/j.abd.2025.501255_bib0200","doi-asserted-by":"crossref","first-page":"45","DOI":"10.4236\/jbise.2025.183003","article-title":"Investigating the impact of GLP-1 receptor agonist-induced fat loss on collagen synthesis and skin elasticity","volume":"18","author":"Sataray-Rodriguez","year":"2025","journal-title":"J Biomed Sci Eng."},{"key":"10.1016\/j.abd.2025.501255_bib0205","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1001\/jamainternmed.2024.2525","article-title":"Semaglutide vs tirzepatide for weight loss in adults with overweight or obesity","volume":"184","author":"Rodriguez","year":"2024","journal-title":"JAMA Intern Med."},{"key":"10.1016\/j.abd.2025.501255_bib0210","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/obesities5020022","article-title":"Injectables pharmacotherapies for obesity: mechanisms, efficacy, and aesthetic implications","volume":"5","author":"Gomes","year":"2025","journal-title":"Obesities."},{"key":"10.1016\/j.abd.2025.501255_bib0215","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1590\/abd1806-4841.20175514","article-title":"Diabetes mellitus and the skin","volume":"92","author":"Mendes","year":"2017","journal-title":"An Bras Dermatol."},{"key":"10.1016\/j.abd.2025.501255_bib0220","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.jdcr.2024.06.001","article-title":"Treatment of insulin resistance with tirzepatide leading to improvement of hair loss","volume":"50","author":"Gordon","year":"2024","journal-title":"JAAD Case Rep."},{"key":"10.1016\/j.abd.2025.501255_bib0225","article-title":"Improvement of recalcitrant folliculitis decalvans with tirzepatide: a case report","volume":"16","author":"Morrissette","year":"2024","journal-title":"Cureus."},{"key":"10.1016\/j.abd.2025.501255_bib0230","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.jdcr.2024.02.023","article-title":"A case of recalcitrant hidradenitis suppurativa concomitantly treated with tirzepatide","volume":"52","author":"Chan","year":"2024","journal-title":"JAAD Case Rep."},{"key":"10.1016\/j.abd.2025.501255_bib0235","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1177\/1203475419874412","article-title":"Weight loss and dietary interventions for hidradenitis suppurativa: a systematic review","volume":"24","author":"Sivanand","year":"2020","journal-title":"J Cutan Med Surg."},{"key":"10.1016\/j.abd.2025.501255_bib0240","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fimmu.2023.1148209","article-title":"Glucagon-like peptide-1: a multi-faceted anti-inflammatory agent","volume":"14","author":"Mehdi","year":"2023","journal-title":"Front Immunol."},{"key":"10.1016\/j.abd.2025.501255_bib0245","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1177\/2042018814543483","article-title":"Effect of glucagon-like peptide-1 receptor agonists in patients with psoriasis","volume":"5","author":"Al-Badri","year":"2014","journal-title":"Ther Adv Endocrinol Metab."},{"key":"10.1016\/j.abd.2025.501255_bib0250","doi-asserted-by":"crossref","first-page":"4500","DOI":"10.1210\/jc.2016-2466","article-title":"The diagnosis and management of lipodystrophy syndromes: a multi-society practice guideline","volume":"101","author":"Brown","year":"2016","journal-title":"J Clin Endocrinol Metab."},{"key":"10.1016\/j.abd.2025.501255_bib0255","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1111\/j.1463-1326.2005.00468.x","article-title":"Effect of three treatment schedules of recombinant methionyl human leptin on body weight in obese adults: a randomized, placebo\u2010controlled trial","volume":"7","author":"Zelissen","year":"2005","journal-title":"Diabetes Obes Metab."},{"key":"10.1016\/j.abd.2025.501255_bib0260","first-page":"756","article-title":"Metabolic improvements with tirzepatide in lipodystrophy: a novel option?","volume":"48","author":"Meral","year":"2025","journal-title":"Diabetes Care."}],"container-title":["Anais Brasileiros de Dermatologia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0365059625001977?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0365059625001977?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,2,20]],"date-time":"2026-02-20T16:19:50Z","timestamp":1771604390000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0365059625001977"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":52,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["S0365059625001977"],"URL":"https:\/\/doi.org\/10.1016\/j.abd.2025.501255","relation":{},"ISSN":["0365-0596"],"issn-type":[{"value":"0365-0596","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Tirzepatide in dermatology: cutaneous adverse events, emerging therapeutic roles, and cosmetic implications \u2013 A comprehensive review","name":"articletitle","label":"Article Title"},{"value":"Anais Brasileiros de Dermatologia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.abd.2025.501255","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Sociedade Brasileira de Dermatologia. Published by Elsevier Espa\u00f1a, S.L.U.","name":"copyright","label":"Copyright"}],"article-number":"501255"}}